IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Katashi NAKASHIMA et al.

Mail Stop: PCT

Serial No. NEW

Attorney Docket No. 2006-0018A

Filed January 31, 2006

TRANSDERMAL PREPARATION [Corresponding to PCT/JP2004/011068 Filed August 3, 2004]

THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT ACCOUNT NO. 23-0975.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed.

1a. [X] This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b.	Π	This In	formation	Disclosure	Statement	is submitted
IU.	11	11112 111	ionnation	Disciosuic	Statement	is sublillition

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) [] the certification of paragraph 2 below is provided, or
- (2) [] the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
- 1c. [] This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

- a. [] that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- b. [] that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.
- 3. [] Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

- 4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
 - a. [] a full or partial English language translation submitted herewith,
 - b. [X] a foreign patent office search report (International Search Report) (in the English language) submitted herewith,
 - c. [X] the concise explanation contained in the specification of the present application at page 1,
 - d. [X] the concise explanation set forth in the attached English language abstract,
 - e. [] the concise explanation set forth below or on a separate sheet attached to the reference:
- 5. [X] A foreign patent office search report (International Search Report) citing one or more of the references is enclosed.

Respectfully submitted,

Katashi NAKASHIMA et al.

Michael R. Davis

Registration No. 25,134

Attorney for Applicants

MRD/pth Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 January 31, 2006

Sheet 1 of 1	•)	()	INFORMA	TION DISCLOSURE STAT	EMENT						
FORM PTO 1449 (m		TMENT OF COMMERC	·F	ATTY DOCKET NO. SERIAL NEW		30/566 502					
PAT	ENT AN	ID TRADEMARK OFFIC	E	APPLICANT Katashi NAKASHI MARIA 1000 1000 31 JAN 2006							
	(Use seve	eral sheets if necessary) I to PTO: January 31, 2		FILING DATE January 31, 2006			GROUP				
				S. PATENT DOCUMENTS	-		<u> </u>				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	Ct	ASS	SUBCLASS	FILING DATE IF APPROPRIATE			
	AA										
	АВ										
	AC										
	AD										
	AE						`.				
	AF								•		
	AG						i				
	АН						•				
	Al										
			FORE	IGN PATENT DOCUMENT	rs_						
		DOCUMENT NUMBER	DATE	COUNTRY	CL	ASS	SUBCLASS	TRANSLATION YES NO			
-	AJ	01/34147	5/2001	WO							
	AK	2001-39873	2/2001	Japan		·					
	AL	10-45597	2/1998	Japan							
	АМ										
	AN										
		OTHER	DOCUMENT(S) (I	ncluding Author, Title, Date,	, Pertinent Pages	, Etc.)					
	AO	Hiroyuki Miyachi et al., "Synthesis and Antimuscarinic Activity of a Series of 4-(1-Imidazolyl)-2, 2-diphenylbutyramides: Discovery of Potent and Subtype-selective Antimuscarinic Agents", Bioorganic & Medicinal Chemistry, 7, pages 1151-1161, 1999.									
e e e e e e e e e e e e e e e e e e e	AP										
	AQ					_	•				
											
EXAMINER				DATE CON	ISIDERED						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of form with next communication to applies the FERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.P./